Advertisement

Theranostic Applications of Lysozyme-Based Nanoparticles

  • Sourav Das
  • Manideep Pabba
  • M. E. Dhushyandhun
  • Chitta Ranjan PatraEmail author
Chapter

Abstract

Nanotechnology has become an integral part in the domain of therapeutic and diagnostic treatment strategies for various diseases. Amidst various nanoparticles, protein-based nanoparticles have got significant importance owing to their lower toxicity and biodegradability. Among several proteins which are being used in making nanoparticles, lysozyme is one of them. Lysozyme, an anti-microbial enzyme, abundant in secretions of human, serves pivotal role in innate immune system. Recently, scientists have been using this biocompatible protein as template or establishment of framework for developing nanoparticles. Additionally, the readily tunable structures of this stabilized protein also assist in tailoring a broad range of nanoparticles. In this prospect, this chapter will emphasize the overview of recent applications of lysozyme-based nanoparticles in anti-microbial therapy, wound healing, etc., and in diagnostic functions such as cell imaging and sensors. Moreover, the properties of lysozyme as well as its various applications (anti-microbial activity, anti-proliferative activity, amyloid formation ability, etc.) are also narrated in an incisive manner. Additionally, the intricate mechanism underlying the interaction of lysozyme protein with the inorganic metal nanoparticles is also illustrated in this chapter. Herein, this chapter renders the challenges and the possible future direction of the lysozyme-based nanoparticles in theranostic applications.

Keywords

Lysozyme Nanoparticles Biological activity Amyloid Theranostic applications 

Abbreviations

A549

Adenocarcinomic human alveolar basal epithelial cells

ABTS

2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)

AgNPs

Silver nanoparticles

AuNCs

Lysozyme-gold nanocluster

CD

Circular dichroism

CF

Cystic fibrosis

CMC

Critical micelle concentrations

COPD

Chronic obstructive pulmonary diseases

CuNCs

Copper nanocluster

EDTA

Ethylenediaminetetraacetic acid

EGF

Epidermal growth factor

FRET

Forster non-radiative energy transfer

FT-IR

Fourier-transform infrared spectroscopy

HeLa

Cervical cancer cells (human)

HGT

Horizontal gene transfer

hLYS

Human lysozyme

HPLC

High-performance liquid chromatography

LOD

Lowest detection limit

LYMB

Lysozyme microbubble

MALDI

Matrix-assisted laser desorption/ionization

MCF-7

Michigan cancer foundation-7

MD

Molecular dynamics

MIC

Minimum inhibitory concentration

NAG-3

N-acetyl-d-glucosamine

NC

Nanoclusters

ND

Nanodiamonds

NHF

Normal human foreskin fibroblast

NP

Nanoparticles

PBS

Phosphate buffered saline

PDRAB

Pan-drug resistant Acinetobacter baumannii

PEI

Polyethyleneimine

rHlys

Recombinant human lysozyme

ROS

Reactive oxygen species

SAP

Serum amyloid p component

SDS

Sodium dodecyl sulfate

snLYZ

Self-assembled nanostructured lysozyme

TDD

Transdermal drug delivery

THB

Theobromine

THP

Theophylline

TMB

3,3′,5,5′-Tetramethylbenzidine

US

Ultrasound

VRE

Vancomycin-resistant Enterococcus faecalis

WT

Wild type

XRD

X-ray crystallography

XTT

2,3-Bis-(2-methoxy-4-nitro5-sulfophenyl)-2H-tetrazolium-5-carboxanilide salt

Notes

Acknowledgement

A generous financial support from DST, New Delhi, for “Nanomission Project” (SR/NM/NS-1252/2013; GAP 570) to CRP is duly acknowledged. SD is thankful to UGC, New Delhi, for Senior Research Fellowships. The authors are thankful to the Director, CSIR-IICT for his support and encouragement and for his keen interest in this work. IICT Manuscript No. is IICT/Pubs./2019/021 dated January 28, 2019 for this manuscript is duly acknowledged.

References

  1. Aghili Z, Taheri S, Zeinabad HA, et al. Investigating the interaction of Fe nanoparticles with lysozyme by biophysical and molecular docking studies. PLoS One. 2016;11:e0164878.CrossRefGoogle Scholar
  2. Ashraf S, Chatha MA, Ejaz W, et al. Lysozyme-coated silver nanoparticles for differentiating bacterial strains on the basis of antibacterial activity. Nanoscale Res Lett. 2014;9:565.CrossRefGoogle Scholar
  3. Bruzzesi MR, Chiancone E, Antonini E. Association-dissociation properties of lysozyme∗. Biochemistry. 1965;4:1796–800.CrossRefGoogle Scholar
  4. Cai H, Yao P. In situ preparation of gold nanoparticle-loaded lysozyme–dextran nanogels and applications for cell imaging and drug delivery. Nanoscale. 2013;5:2892–900.CrossRefGoogle Scholar
  5. Callewaert L, Michiels CW. Lysozymes in the animal kingdom. J Biosci. 2010;35:127–60.CrossRefGoogle Scholar
  6. Callewaert L, Van Herreweghe JM, Vanderkelen L, et al. Guards of the great wall: bacterial lysozyme inhibitors. Trends Microbiol. 2012;20:501–10.CrossRefGoogle Scholar
  7. Charernsriwilaiwat N, Opanasopit P, Rojanarata T, et al. Lysozyme-loaded, electrospun chitosan-based nanofiber mats for wound healing. Int J Pharm. 2012;427:379–84.CrossRefGoogle Scholar
  8. Chen WY, Lin JY, Chen WJ, Luo LY, et al. Functional gold nanoclusters as antimicrobial agents, for antibiotic-resistant bacteria. Nanomedicine (Lond). 2010;5:755–64.CrossRefGoogle Scholar
  9. Cho K, Wang X, Nie S, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14:1310–6.CrossRefGoogle Scholar
  10. Choi Y, Moody IS, Sims PC, et al. Single-molecule lysozyme dynamics monitored by an electronic circuit. Science. 2012;335:319–24.CrossRefGoogle Scholar
  11. Cole AM, Liao HI, Stuchlik O, et al. Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol. 2002;169:6985–91.CrossRefGoogle Scholar
  12. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008;3:133–49.CrossRefGoogle Scholar
  13. During K, Porsch P, Mahn A, et al. The non-enzymatic microbicidal activity of lysozymes. FEBS Lett. 1999;449:93–100.CrossRefGoogle Scholar
  14. Eby DM, Luckarift HR, Johnson GR, et al. Hybrid antimicrobial enzyme and silver nanoparticle coatings for medical instruments. ACS Appl Mater Interfaces. 2009a;1:1553–60.CrossRefGoogle Scholar
  15. Eby DM, Schaeublin NM, Farrington KE, et al. Lysozyme catalyzes the formation of antimicrobial silver nanoparticles. ACS Nano. 2009b;3:984–94.CrossRefGoogle Scholar
  16. Fleming A, Wright Almroth E. On a remarkable bacteriolytic element found in tissues and secretions. Proc Royal Soc London. 1922;93:306–17.CrossRefGoogle Scholar
  17. Gasior-Chrzan B. Effect of ovalbumin lysozyme on healing of standard skin wounds in Guinea pigs. Przegl Dermatol. 1988;75:431–4.PubMedGoogle Scholar
  18. Ghosh R, Sahoo AK, Ghosh SS, et al. Blue-emitting copper nanoclusters synthesized in the presence of lysozyme as candidates for cell labeling. ACS Appl Mater Interfaces. 2014;6:3822–8.CrossRefGoogle Scholar
  19. Gill A, Scanlon TC, Osipovitch DC, et al. Crystal structure of a charge engineered human lysozyme having enhanced bactericidal activity. PLoS One. 2011;6:e16788.CrossRefGoogle Scholar
  20. Guo TK, Zhao X, Xie XD, et al. The anti-proliferative effects of recombinant human lysozyme on human gastric cancer cells. J Int Med Res. 2007;35:353–60.CrossRefGoogle Scholar
  21. Helmfros L, Bergkvist L, Brorsson A-C. Serum amyloid P component ameliorates neuroligical damage caused by expressing a lysozyme variant in the central nervous system of Drosophila melanogaster. PLoS One. 2016;11:e0159294.CrossRefGoogle Scholar
  22. Hughey VL, Johnson EA. Antimicrobial activity of lysozyme against bacteria involved in food spoilage and food-borne disease. Appl Environ Microbiol. 1987;53:2165–70.PubMedPubMedCentralGoogle Scholar
  23. Huh AJ, Kwon YJ. “Nanoantibiotics”: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J Control Release. 2011;156:128–45.CrossRefGoogle Scholar
  24. Jafari M, Mehrnejad F. Molecular insight into human lysozyme and its ability to form amyloid fibrils in high concentrations of sodium dodecyl sulfate: a view from molecular dynamics simulations. PLoS One. 2016;11:e0165213.CrossRefGoogle Scholar
  25. Kim HJ, Zhang K, Moore L, et al. Diamond nanogel-embedded contact lenses mediate lysozyme-dependent therapeutic release. ACS Nano. 2014;8:2998–3005.CrossRefGoogle Scholar
  26. Li H, Li S, Tian P, et al. Prevention of bacterial contamination of a silica matrix containing entrapped beta-galactosidase through the action of covalently bound lysozymes. Molecules. 2017;22:E377.CrossRefGoogle Scholar
  27. Liao AH, Hung CR, Chen HK, et al. Ultrasound-mediated EGF-coated-microbubble cavitation in dressings for wound-healing applications. Sci Rep. 2018;8:8327.CrossRefGoogle Scholar
  28. Lin YH, Tseng WL. Ultrasensitive sensing of Hg2+ and CH3Hg+ based on the fluorescence quenching of lysozyme type VI-stabilized gold nanoclusters. Anal Chem. 2010;82:9194–200.CrossRefGoogle Scholar
  29. Mahanta S, Paul S, Srivastava A, et al. Stable self-assembled nanostructured hen egg white lysozyme exhibits strong anti-proliferative activity against breast cancer cells. Colloids Surf B Biointerfaces. 2015;130:237–45.CrossRefGoogle Scholar
  30. Murakami K, Lagarde M, Yuki Y. Identification of minor proteins of human colostrum and mature milk by two-dimensional electrophoresis. Electrophoresis. 1998;19:2521–7.CrossRefGoogle Scholar
  31. Osserman EF. Postulated relationships between lysozyme and immunoglobulins as mediators of macrophage and plasma cell functions. Adv Pathobiol. 1976;4:98–105.PubMedGoogle Scholar
  32. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine (Lond). 2012;8:147–66.CrossRefGoogle Scholar
  33. Peeters T, Vantrappen G. The Paneth cell: a source of intestinal lysozyme. Gut. 1975;16:553–8.CrossRefGoogle Scholar
  34. Picheth GF, et al. Lysozyme-triggered epidermal growth factor release from bacterial cellulose membranes controlled by smart nanostructured films. J Pharm Sci. 2014;103:3958–65.CrossRefGoogle Scholar
  35. Roy S, Saxena SK, Mishra S, et al. Ecofriendly gold nanoparticles - lysozyme interaction: thermodynamical perspectives. J Photochem Photobiol B. 2017;174:284–90.CrossRefGoogle Scholar
  36. Russell BA, Jachimska B, Komorek P, et al. Lysozyme encapsulated gold nanoclusters: effects of cluster synthesis on natural protein characteristics. Phys Chem Chem Phys. 2017;19:7228–35.CrossRefGoogle Scholar
  37. Salton MR. The properties of lysozyme and its action on microorganisms. Bacteriol Rev. 1957;21:82–100.PubMedPubMedCentralGoogle Scholar
  38. Scanlon TC, et al. Enhanced antimicrobial activity of engineered human lysozyme. ACS Chem Biol. 2010;5:809–18.CrossRefGoogle Scholar
  39. Sharma P, Verma N, Singh PK, et al. Characterization of heat induced spherulites of lysozyme reveals new insight on amyloid initiation. Sci Rep. 2016;6:22475.CrossRefGoogle Scholar
  40. Shire SJ. Stability characterization and formulation development of recombinant human deoxyribonuclease I [Pulmozyme (dornase alpha)]. Pharm Biotechnol. 1996;9:393–426.CrossRefGoogle Scholar
  41. Sonu VK, Islam MM, Rohman MA, et al. Lysozyme binding ability toward psychoactive stimulant drugs: modulatory effect of colloidal metal nanoparticles. Colloids Surf B Biointerfaces. 2016;146:514–22.CrossRefGoogle Scholar
  42. Sun HY, Lu DT, Xian M, et al. A lysozyme-stabilized silver nanocluster fluorescent probe for the detection of sulfide ions. Anal Methods. 2016;8:4328–33.CrossRefGoogle Scholar
  43. Tarhini M, Greige-Gerges H, Elaissari A. Protein-based nanoparticles: from preparation to encapsulation of active molecules. Int J Pharm. 2017;522:172–97.CrossRefGoogle Scholar
  44. Tripathy N, Ahmad R, Bang SH, et al. Tailored lysozyme-ZnO nanoparticle conjugates as nanoantibiotics. Chem Commun. 2014;50:9298–301.CrossRefGoogle Scholar
  45. Venkataramani S, Truntzer J, Coleman DR. Thermal stability of high concentration lysozyme across varying pH: a Fourier transform infrared study. J Pharm Bioallied Sci. 2013;5:148–53.CrossRefGoogle Scholar
  46. Wang C, Shu SL, Yao YG, et al. A fluorescent biosensor of lysozyme-stabilized copper nanoclusters for the selective detection of glucose. RSC Adv. 2015;5:101599–606.CrossRefGoogle Scholar
  47. Wang G, Hou H, Wang S, et al. Exploring the interaction of silver nanoparticles with lysozyme: binding behaviors and kinetics. Colloids Surf B Biointerfaces. 2017;157:138–45.CrossRefGoogle Scholar
  48. Yadav I, Aswal VK, Kohlbrecher J. Interaction of lysozyme protein with different sized silica nanoparticles and their resultant structures. AIP Conf Proc. 2016;1731:050093.CrossRefGoogle Scholar
  49. Ye JL, Wang CB, Chen XH, et al. Marine lysozyme from a marine bacterium that inhibits angiogenesis and tumor growth. Appl Microbiol Biotechnol. 2008;77:1261–7.CrossRefGoogle Scholar
  50. Yguerabide J, Yguerabide EE. Light-scattering submicroscopic particles as highly fluorescent analogs and their use as tracer labels in clinical and biological applications—II. Experimental characterizations. Anal Biochem. 1998;262:137–56.CrossRefGoogle Scholar
  51. Yu CJ, Chen TH, Jiang JY, et al. Lysozyme-directed synthesis of platinum nanoclusters as a mimic oxidase. Nanoscale. 2014;6:9618–24.CrossRefGoogle Scholar
  52. Zhou Y, Kong Y, Kundu S, et al. Antibacterial activities of gold and silver nanoparticles against Escherichia coli and bacillus Calmette-Guérin. J Nanobiotechnol. 2012;10:19.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Sourav Das
    • 1
    • 2
  • Manideep Pabba
    • 2
  • M. E. Dhushyandhun
    • 2
  • Chitta Ranjan Patra
    • 1
    • 2
    Email author
  1. 1.Academy of Scientific and Innovative Research (AcSIR)GhaziabadIndia
  2. 2.Department of Applied BiologyCSIR-Indian Institute of Chemical TechnologyHyderabadIndia

Personalised recommendations